• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Celcuity Inc.

Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer
July 18, 2022
From Celcuity Inc.
Via AccessWire
Tickers CELC
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
May 26, 2022
From Celcuity Inc.
Via AccessWire
Tickers CELC
Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates
May 16, 2022
From Celcuity Inc.
Via AccessWire
Tickers CELC
Celcuity Inc. Announces $100 Million Private Placement
May 16, 2022
From Celcuity Inc.
Via AccessWire
Tickers CELC
Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call
May 09, 2022
From Celcuity Inc.
Via AccessWire
Tickers CELC
Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences
April 05, 2022
From Celcuity Inc.
Via AccessWire
Tickers CELC
Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates
March 23, 2022
From Celcuity Inc.
Via AccessWire
Tickers CELC
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2021 Financial Results and Webcast/Conference Call
March 16, 2022
From Celcuity Inc.
Via AccessWire
Tickers CELC
Celcuity to Participate in the Cowen 42nd Annual Health Care Conference
March 02, 2022
From Celcuity Inc.
Via AccessWire
Tickers CELC
Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update
January 18, 2022
From Celcuity Inc.
Via AccessWire
Tickers CELC
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symposium
December 10, 2021
From Celcuity Inc.
Via AccessWire
Tickers CELC
Celcuity to Present at the 2021 San Antonio Breast Cancer Symposium
December 02, 2021
From Celcuity Inc.
Via AccessWire
Tickers CELC
Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process Development
November 29, 2021
From Celcuity Inc.
Via AccessWire
Tickers CELC
Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (palbociclib) for Planned Phase 3 Clinical Trial
November 15, 2021
From Celcuity Inc.
Via AccessWire
Tickers CELC
Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences
November 09, 2021
From Celcuity Inc.
Via AccessWire
Tickers CELC
Celcuity Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 08, 2021
From Celcuity Inc.
Via AccessWire
Topics Intellectual Property
Tickers CELC
Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference Call
October 29, 2021
From Celcuity Inc.
Via AccessWire
Tickers CELC
Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases
October 18, 2021
From Celcuity Inc.
Via Business Wire
Tickers CELC
Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 09, 2021
From Celcuity Inc.
Via AccessWire
Tickers CELC
Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference
August 05, 2021
From Celcuity Inc.
Via AccessWire
Tickers CELC
Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast
August 02, 2021
From Celcuity Inc.
Via AccessWire
Tickers CELC
Celcuity to Participate in the William Blair Biotech Focus Conference
July 08, 2021
From Celcuity Inc.
Via AccessWire
Tickers CELC
Celcuity Announces Pricing of Follow-on Offering
June 28, 2021
From Celcuity Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers CELC
Celcuity Announces Launch of Follow-on Offering
June 28, 2021
From Celcuity Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers CELC
Celcuity Announces Appointment of Dr. Igor Gorbatchevsky as VP of Clinical Development and Jill Krause as VP of Clinical Operations
June 09, 2021
From Celcuity Inc.
Via AccessWire
Tickers CELC
Celcuity Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 10, 2021
From Celcuity Inc.
Via AccessWire
Tickers CELC
Celcuity Inc. Schedules Release of First Quarter 2021 Financial Results and Webcast
April 26, 2021
From Celcuity Inc.
Via AccessWire
Tickers CELC
Celcuity Presents Data at AACR Annual Meeting Assessing Gedatolisib, a pan-PI3K/mTOR Inhibitor, in HER2-negative Breast and Ovarian Cancer Patient Tumors with Hyperactive RAS Network Signaling
April 12, 2021
From Celcuity Inc.
Via AccessWire
Tickers CELC
Celcuity Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus Ibrance® and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides Corporate Update
April 08, 2021
From Celcuity Inc.
Via Business Wire
Tickers CELC
Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer
April 08, 2021
From Celcuity Inc.
Via Business Wire
Tickers CELC
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap